Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 294

1.

Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling.

Xu H, Sun Y, You B, Huang CP, Ye D, Chang C.

Cancer Lett. 2020 Mar 1;472:151-164. doi: 10.1016/j.canlet.2019.12.014. Epub 2019 Dec 14.

2.

Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.

Hu L, Sun Y, Luo J, He X, Ye M, Li G, Zhang Y, Bai J, Zhang D, Chang C.

Oncogene. 2019 Nov 20. doi: 10.1038/s41388-019-1070-5. [Epub ahead of print]

PMID:
31748715
3.

Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling.

Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C, Xiang Z, Sun Y, Messing E, Zu X, Chang C.

Oncogene. 2020 Jan;39(3):574-586. doi: 10.1038/s41388-019-0964-6. Epub 2019 Sep 10.

PMID:
31506605
4.

Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.

Shi H, Sun Y, He M, Yang X, Hamada M, Fukunaga T, Zhang X, Chang C.

Oncogene. 2020 Jan;39(3):530-545. doi: 10.1038/s41388-019-0962-8. Epub 2019 Sep 9.

5.

Deficiency in Androgen Receptor Aggravates the Depressive-Like Behaviors in Chronic Mild Stress Model of Depression.

Hung YY, Huang YL, Chang C, Kang HY.

Cells. 2019 Sep 2;8(9). pii: E1021. doi: 10.3390/cells8091021.

6.

ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.

Huang CP, Chen J, Chen CC, Liu G, Zhang Y, Messing E, Yeh S, Chang C.

J Exp Clin Cancer Res. 2019 Jun 24;38(1):275. doi: 10.1186/s13046-019-1258-0.

7.

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.

Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, Xu W, Niu Y, Cheng L, Maity SN, Jiang R, Chang C.

Nat Commun. 2019 Jun 12;10(1):2571. doi: 10.1038/s41467-019-09784-9.

8.

The Protective Roles of Estrogen Receptor β in Renal Calcium Oxalate Crystal Formation via Reducing the Liver Oxalate Biosynthesis and Renal Oxidative Stress-Mediated Cell Injury.

Zhu W, Zhao Z, Chou FJ, Zuo L, Liu T, Bushinsky D, Chang C, Zeng G, Yeh S.

Oxid Med Cell Longev. 2019 Apr 17;2019:5305014. doi: 10.1155/2019/5305014. eCollection 2019.

9.

Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.

Zhu S, Tian H, Niu X, Wang J, Li X, Jiang N, Wen S, Chen X, Ren S, Xu C, Chang C, Flores-Morales A, Shang Z, Sun Y, Niu Y.

Oncogene. 2019 Jun;38(24):4885. doi: 10.1038/s41388-019-0827-1.

PMID:
31048775
10.

Androgen receptor regulates ASS1P3/miR-34a-5p/ASS1 signaling to promote renal cell carcinoma cell growth.

Wang K, Sun Y, Guo C, Liu T, Fei X, Chang C.

Cell Death Dis. 2019 Apr 18;10(5):339. doi: 10.1038/s41419-019-1330-x.

11.

Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals.

Zhu W, Zhao Z, Chou F, Zuo L, Liu T, Yeh S, Bushinsky D, Zeng G, Chang C.

Cell Death Dis. 2019 Mar 20;10(4):275. doi: 10.1038/s41419-019-1358-y.

12.

Early Stage Biomarkers Screening of Prostate Cancer Based on Weighted Gene Coexpression Network Analysis.

Meng L, Li Y, Ren J, Shi T, Men J, Chang C.

DNA Cell Biol. 2019 May;38(5):468-475. doi: 10.1089/dna.2018.4406. Epub 2019 Mar 5.

PMID:
30835547
13.

LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.

Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang B, Dong Q, Jiang N, Flores-Morales A, Chang C, Niu Y.

Nucleic Acids Res. 2019 May 7;47(8):4211-4225. doi: 10.1093/nar/gkz108.

14.

Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.

Zhu S, Tian H, Niu X, Wang J, Li X, Jiang N, Wen S, Chen X, Ren S, Xu C, Chang C, Flores-Morales A, Shang Z, Sun Y, Niu Y.

Oncogene. 2019 Jun;38(24):4875-4884. doi: 10.1038/s41388-019-0750-5. Epub 2019 Feb 15. Erratum in: Oncogene. 2019 May 2;:.

15.

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.

Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, Yeh S, Chang C.

EBioMedicine. 2019 Feb;40:504-516. doi: 10.1016/j.ebiom.2018.12.050. Epub 2019 Jan 26.

16.

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.

Wu G, Sun Y, Xiang Z, Wang K, Liu B, Xiao G, Niu Y, Wu D, Chang C.

Cell Death Dis. 2019 Jan 15;10(2):37. doi: 10.1038/s41419-018-1048-1.

17.

Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.

Xiao Y, Sun Y, Liu G, Zhao J, Gao Y, Yeh S, Gong L, Chang C.

Cancer Lett. 2019 Mar 1;444:175-187. doi: 10.1016/j.canlet.2018.11.004. Epub 2018 Nov 15.

PMID:
30448543
18.

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D.

Bladder Cancer. 2018 Oct 3;4(Suppl 1):S1-S43. doi: 10.3233/BLC-189037. No abstract available.

19.

Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.

Zhang M, Sun Y, Meng J, Zhang L, Liang C, Chang C.

Cancer Lett. 2019 Feb 1;442:483-490. doi: 10.1016/j.canlet.2018.11.008. Epub 2018 Nov 10.

PMID:
30423407
20.

Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.

Luo J, Tian J, Chou F, Lin C, Xing EZ, Zuo L, Niu Y, Yeh S, Chang C.

Cancer Lett. 2019 Mar 1;444:35-44. doi: 10.1016/j.canlet.2018.09.025. Epub 2018 Sep 21.

PMID:
30248372

Supplemental Content

Loading ...
Support Center